IMP-4510

FLT1

Recombinant human VEGFR1 (P17948-1) extracellular domain (Met1-Asn756) was expressed fused with a polyhistidine tag at the C-terminus.

Vascular endothelial growth factor receptor 1, also known as VEGFR-1, Fms-like tyrosine kinase 1, Tyrosine-protein kinase FRT, Tyrosine-protein kinase receptor FLT, Vascular permeability factor receptor and FLT1, is a single-pass type I membrane protein and secreted protein which belongs to theprotein kinase superfamily, Tyr protein kinase family and CSF-1/PDGF receptor subfamily. VEGFR-1 / FLT1 contains sevenIg-like C2-type (immunoglobulin-like) domains and oneprotein kinase domain. VEGFR-1 / FLT1 is expressed mostly in normal lung, but also in placenta, liver, kidney, heart and brain tissues. It is specifically expressed in most of the vascular endothelial cells, and also expressed in peripheral blood monocytes. VEGFR-1 / FLT1 is not expressed in tumor cell lines. VEGFR-1 / FLT1 is an essential receptor tyrosine kinase that regulates mammalian vascular development and embryogenesis. EGF-induced angiogenesis requires inverse regulation of VEGFR-1 and VEGFR-2 in tumor-associated endothelial cells. VEGFR-1 / FLT1 is a receptor for VEGF, VEGFB and PGF. It has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability.

HEK293

Human

C-His

Ser 27

Lyophilized from sterile PBS, pH 7.4, 5 % trehalose, 5% mannitol and 0.01% Tween80.

The secreted recombinant human VEGFR1 consists of 741 amino acids with the predicted molecular mass of 83.7 kDa. As a result of glycosylation, rhVEGFR1 migrates as an approximately 110-120 kDa band in SDS-PAGE under reducing conditions.

Met1-Asn756

< 1.0 EU/μg of the protein as determined by the LAL method

> 97 % as determined by SDS-PAGE

Samples are stable for up to twelve months from date of receipt at -20 to -80 centigrade.
Store it under sterile conditions at -20 to -80 centigrade. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

Measured by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells (HUVEC) (Conn, G. et al., 1990, Proc. Natl. Acad. Sci. USA 87:1323.). The ED50 for this effect is typically 10-40 ng/mL in the presence of 10 ng/mL human VEGF165.